| Literature DB >> 28967616 |
Yongping Zhang1, Wei Mu2, Haoyi Wang3.
Abstract
The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise. Gene editing holds tremendous potential for further improvements of T cell therapy. Here we review the applications of gene editing in various T cell therapies, focusing on antiviral strategies and cancer immunotherapies, and discuss the challenges and future prospects.Entities:
Keywords: CRISPR-Cas9; Gene editing; T cells
Mesh:
Year: 2017 PMID: 28967616 DOI: 10.1016/j.jgg.2017.09.002
Source DB: PubMed Journal: J Genet Genomics ISSN: 1673-8527 Impact factor: 4.275